Key Points
Novo Nordisk is ending its lawsuit with Hims & Hers and the two have now become partners.
Ozempic and Wegovy will both be sold on the Hims & Hers platform at the same low price as other direct providers.
This could open up new avenues of growth with other pharmaceutical brands and the peptide market in 2026.
- 10 stocks we like better than Novo Nordisk ›
Earlier this year, Novo Nordisk (NYSE: NVO) sued Hims & Hers (NYSE: HIMS), which investors thought was the end of the telehealth company.
Today, Novo not only dropped their lawsuit, they announced a partnership with Hims & Hers that will bring its branded products to the platform at a low price. Shares of Hims & Hers responded by jumping 40% and this may only be the start of the pop in shares as peptides and other treatments come to the Hims & Hers platform.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
*Stock prices used were end-of-day prices of March 9, 2026. The video was published on March 9, 2026.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $534,008!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,090,073!*
Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 190% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 9, 2026.
Travis Hoium has positions in Hims & Hers Health. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
